Navigation Links
GSK Update on FDA Review of Promacta(R) (Eltrombopag)
Date:6/20/2008

PHILADELPHIA, Pa. June 20 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced that the United States Food and Drug Administration has extended the priority review period for PROMACTA(R) (eltrombopag) for the short-term treatment of previously treated patients with chronic idiopathic thrombocytopenic purpura, as they require more time to review the application. The Prescription Drug User Fee action date has been extended to September 19, 2008.

On May 30, the Oncology Drugs Advisory Committee unanimously voted, 16-0, that eltrombopag demonstrated a favorable risk-benefit profile for the short-term treatment of patients with chronic idiopathic thrombocytopenic purpura, or ITP.

GSK will continue to work with the FDA towards the approval of eltrombopag in order to provide physicians and chronic ITP patients with a novel option for treating this difficult disease.

About Promacta(R) (Eltrombopag)

Eltrombopag, a novel oral thrombopoeitin (TPO) receptor agonist, if approved, would be the first oral short-term treatment of previously treated patients with chronic ITP to increase platelet counts and reduce or prevent bleeding. In the pivotal studies, the most common adverse events observed in patients taking eltrombopag were headache, common cold, and nausea.

About GlaxoSmithKline

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline at http://www.gsk.com.

US Media inquiries: Jeff McLaughlin 1 919 483 2839
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. XTENT Announces European Regulatory Update
2. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
3. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
4. Genmab Announces Updates on Phase III Cancer Studies
5. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
6. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
7. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
8. UPDATE: Infant Primates Given Vaccines on U.S. Childrens Immunization Schedule Develop Behavioral Symptoms of Autism
9. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
10. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
11. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... --  Millar, Inc. , a leader in catheter-based and ... of Craig Thummel , President/CEO and member of ... to the Company. The Company also announced its leadership ... Executive Management team as his successors. The Board of ... of Sales and Marketing, as President, and also a ...
(Date:6/30/2015)... 2015 Dipexium Pharmaceuticals, Inc. (Nasdaq: ... on the development and commercialization of Locilex® (pexiganan ... previously announced underwritten public offering of 1,480,000 shares ... over-allotment option in full to purchase an additional ... net proceeds to Dipexium are expected to be ...
(Date:6/30/2015)... , June 24, 2015 ... the addition of the "Global Array Instruments ... The global array instruments market to grow ... period 2014-2019 The global array instruments market ... protein microarrays, and others including tissue microarrays and ...
Breaking Medicine Technology:Millar, Inc. Announces Leadership Changes 2Millar, Inc. Announces Leadership Changes 3Dipexium Announces Closing of Public Offering of Common Stock 2Dipexium Announces Closing of Public Offering of Common Stock 3Global Array Instruments Market 2015-2019 - Advances in Personalized Medicines with Affymetrix, Agilent Technologies & Illumina Dominating 2
... Biosciences, Inc., a privately held company leading the development ... Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President and ... College of Chest Physicians (ACCP) Coagulation and Heart Disease ...  The abstract is titled "Sustained Inhibition of Factor IXa ...
... JEDDAH, Saudi Arabia, Nov. 2, 2010 The Saudi ... it has signed an agreement with Varian Medical Systems ... for magnetic resonance-guided radiation therapy (MRgRT™). Under ... treatment solution that combines IMRIS, unique movable magnetic resonance ...
Cached Medicine Technology:Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010 2Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010 3Saudi Arabia's King Abdullah International Research Center Signs With Varian Medical Systems and IMRIS for Future Technology for Use in Radiotherapy 2Saudi Arabia's King Abdullah International Research Center Signs With Varian Medical Systems and IMRIS for Future Technology for Use in Radiotherapy 3Saudi Arabia's King Abdullah International Research Center Signs With Varian Medical Systems and IMRIS for Future Technology for Use in Radiotherapy 4
(Date:6/30/2015)... Winston-Salem, NC (PRWEB) , ... June 30, 2015 , ... ... Northern Virginia” title in a recent online poll at http://scoutology.com/novaburgerwars and was ... issue to be published in August 2015. , Red Hot & Blue President Randy ...
(Date:6/30/2015)... Angeles, CA (PRWEB) , ... June 30, 2015 ... ... Physicians News Digest discussed the advantages that fat transfer procedures had over ... reconstruction using fat transfer techniques create breasts that “look and feel natural,” have ...
(Date:6/30/2015)... ... , ... New Energy Works Timberframers invites the public to join their timber ... and beam raisings offer a chance to witness the culmination of months of planning, ... important and exciting event – it is an age-old craft where the bones of ...
(Date:6/30/2015)... ... June 30, 2015 , ... Board certified otolaryngologist Dr. Marcelo ... . , Dr. Antunes is a fellowship trained facial plastic ... In addition to performing cosmetic and reconstructive surgery on the face, he enjoys ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... test to help oncologists provide personalized cancer treatment, will be available through ... the oncologist with valuable insight on how a specific patient’s cancer cells ...
Breaking Medicine News(10 mins):Health News:Red Hot & Blue BBQ Restaurants Voted "Best Burger" in Virginia and "Best Barbecue" in Texas 2Health News:Red Hot & Blue BBQ Restaurants Voted "Best Burger" in Virginia and "Best Barbecue" in Texas 3Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 3Health News:Join New Energy Works Timberframers in Raising the Frames in Western New York 2Health News:Join New Energy Works Timberframers in Raising the Frames in Western New York 3Health News:Join New Energy Works Timberframers in Raising the Frames in Western New York 4Health News:Atlanta Otolaryngologist Dr. Marcelo Antunes Joins Northwest ENT and Allergy Center 2Health News:Atlanta Otolaryngologist Dr. Marcelo Antunes Joins Northwest ENT and Allergy Center 3Health News:Correct Chemo Joins NextGxDx Online Genetic Testing Marketplace 2Health News:Correct Chemo Joins NextGxDx Online Genetic Testing Marketplace 3
... 25 The University of Texas ... add Elekta,s Leksell Gamma Knife (R) Perfexion(TM), ... to treat one or more lesions in the ... oncology department.(Photo: http://www.newscom.com/cgi-bin/prnh/20090225/CL74742 )"Leksell Gamma Knife ...
... CAMBRIDGE, Mass. and GAITHERSBURG, Md., Feb. 25 ... Inc., a systems biology company focused on ... better develop novel therapeutics, molecular diagnostics and ... signed a partnership agreement with Gene Logic, ...
... Feb. 25 Aton Pharma, Inc., a,diversified specialty ... marketing rights to the TIMOPTIC(R) product line from ... non-selective beta-adrenergic receptor,blocking agent indicated for the treatment ... or open-angle glaucoma. As many as 2.25,million Americans ...
... Head Company,s Network of International Subsidiaries and DistributorsWESTFORD, Mass., ... CYNO ), a leading developer and manufacturer of ... announced the appointment of William T. Kelley as Senior ... responsible for the company,s direct subsidiaries in four European ...
... also urges higher cigarette taxes, more oversight of advertising ... All tobacco products in the United States should be ... released Wednesday by a panel of 26 of the ... "Bold thinking is required to reverse the catastrophic projections ...
... Maine, Feb. 25 Millions of Americans live without ... services provided by non-profit dental clinics become increasingly important. ... of Maine Dental Health for AllTM program is helping ... with an estimated 134,000 additional patient visits since its ...
Cached Medicine News:Health News:M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments 2Health News:M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments 3Health News:Genstruct and Gene Logic Collaborate on Systems Toxicology 2Health News:Genstruct and Gene Logic Collaborate on Systems Toxicology 3Health News:Genstruct and Gene Logic Collaborate on Systems Toxicology 4Health News:Aton Pharma Acquires U.S. TIMOPTIC(R) 2Health News:Aton Pharma Acquires U.S. TIMOPTIC(R) 3Health News:Cynosure Appoints William T. Kelley as Senior Vice President of International Sales 2Health News:Cynosure Appoints William T. Kelley as Senior Vice President of International Sales 3Health News:Experts Call for FDA Regulation of Tobacco Products 2Health News:Tom's of Maine Dental Health for All(TM) Program Works With Customers and Retailers to Provide Access to Oral Health Care 2Health News:Tom's of Maine Dental Health for All(TM) Program Works With Customers and Retailers to Provide Access to Oral Health Care 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: